Avalo Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
AVTX Nasdaq 2836 www.avalotx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Avalo Therapeutics, Inc.

Avalo Therapeutics Eyes Q2 2026 Phase IIb LOTUS Readout for AVTX-009 in Hidradenitis Suppurativa - Feb 11th, 2026 4:39 pm
Avalo Therapeutics to Participate in Upcoming Investor Conferences - Feb 4th, 2026 5:00 am
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - Nov 17th, 2025 2:30 pm
Leukocyte Adhesion Deficiency Market Analysis and Forecast, 2025-2035, Featuring Rocket Pharmaceuticals, Avalo Therapeutics, Orpha Labs, and AUG Therapeutics - Nov 12th, 2025 9:25 am
Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates - Nov 6th, 2025 5:00 am
Piper Sandler Maintains Bullish $48 Price Target on Avalo Therapeutics (AVTX) - Oct 29th, 2025 9:57 am
Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa - Oct 29th, 2025 5:00 am
We Think Avalo Therapeutics (NASDAQ:AVTX) Can Afford To Drive Business Growth - Oct 28th, 2025 6:31 am
Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources - Oct 1st, 2025 5:00 am
Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors - Sep 22nd, 2025 5:00 am
Institutional investors own a significant stake of 34% in Avalo Therapeutics, Inc. (NASDAQ:AVTX) - Sep 14th, 2025 8:15 am
Target downgraded, Salesforce upgraded: Wall Street's top analyst calls - Aug 15th, 2025 7:32 am
Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates - Aug 7th, 2025 5:00 am
Avalo Adds Dr. Rita Jain to Board as LOTUS Trial Advances - Jul 2nd, 2025 8:03 pm
Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors - Jun 18th, 2025 5:00 am
Avalo Therapeutics to Participate in The Citizens Life Sciences Conference - Apr 30th, 2025 5:00 am
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board - Mar 26th, 2025 5:00 am
Avalo Reports 2024 Financial Results and Recent Business Updates - Mar 20th, 2025 5:00 am